deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03590652

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

Sponsor: Celgene

Conditions Relapsed/Refractory Multiple Myeloma
Interventions Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML) Dexamethasone Ixazomib Pomalidomide
Updated 15 times since 2018 Last updated: Oct 18, 2025 Started: Oct 17, 2018 Primary completion: Jul 2, 2025 Completion: Jul 2, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The trial met its primary endpoint.

Other terminated trials from Celgene

See all terminations from Celgene

Other Relapsed/Refractory Multiple Myeloma trials with similar outcome

Browse all Relapsed/Refractory Multiple Myeloma trials

This PHASE2 trial investigates Relapsed/Refractory Multiple Myeloma and is currently terminated or withdrawn. Celgene leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Feb 2020 · 12 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~May 2023 · 13 months · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~Jun 2024 · 4 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Feb 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Apr 2022 — May 2023 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Feb 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  7. Feb 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  8. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

  10. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
  • Janssen, LP
  • Takeda
  • University of California, San Diego
Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations